SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date  of  Report  (Date  of earliest event reported)   OCTOBER 19, 1995 ENZON,

INC.

                  (Exact name  of  registrant  as  specified  in  its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)


        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)






ITEM 5.  OTHER EVENTS

     Enzon,  Inc.  ("Enzon"  or  the  "Company") has been advised by Sanofi
Winthrop,  Inc. that the Phase III clinical  trial  of  DISMUTEC
(pegorgotein) in patients with severe closed head injury has been evaluated
and fails to  show  a  statistically  significant  difference  between  the
treatment  group  and  the  control group.  DISMUTEC, the enzyme superoxide
dismutase modified with Enzon's  proprietary PEG-technology, is designed to
decrease tissue injury caused by ischemia  or  trauma in severe closed head
injury   patients.   Through  modification  with  Enzon's   PEG-technology,
DISMUTEC exhibited longer circulating half-life and reduced immunogenicity;
however,  the   drug   showed  insufficient  therapeutic  effect  for  this
indication.  The Company believes the results of the clinical trial have no
immediate impact on the  Company  from an earnings or cash flow perspective
and that these results do not reflect  adversely  on  the  Company's  other
products or PEG-technology.





                            SIGNATURES


     Pursuant  to  the requirements of the Securities Exchange Act of 1934,

the Registrant has duly  caused  this  report to be signed on its behalf by

the undersigned hereunto duly authorized.




Dated:  October 20, 1995




                                              ENZON, INC.
                                             (Registrant)

                           By:   /S/ KENNETH J. ZUERBLIS  Kenneth J. Zuerblis
                                     Vice President, Finance
                                     (Principal Financial and
                                     Accounting Officer)